Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer

(2016) J S Ankeny et al.   BRITISH JOURNAL OF CANCER

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

(2016) Geoffrey R. Oxnard et al.   JOURNAL OF CLINICAL ONCOLOGY

Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment

(2016) Puey Ling Chia et al.   LUNG CANCER

Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer

(2016) Yu Yao et al.   Oncotarget

First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

(2015) Y.-L. Wu et al.   ANNALS OF ONCOLOGY

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

(2015) T. K. Sundaresan et al.   CLINICAL CANCER RESEARCH

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

(2015) Kenneth S. Thress et al.   LUNG CANCER

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients

(2015) Raffaella Pasquale et al.   PHARMACOGENOMICS

Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

(2015) Niki Karachaliou et al.   JAMA Oncology

Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer

(2014) Maria D. Lozano et al.   CANCER CYTOPATHOLOGY

Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer

(2014) Hideharu Kimura et al.   LUNG CANCER

Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial

(2014) Susana Benlloch et al.   PLoS One

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

(2013) M. Beau-Faller et al.   ANNALS OF ONCOLOGY

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer

(2013) E S Lianidou et al.   BRITISH JOURNAL OF CANCER

EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients

(2013) Umberto Malapelle et al.   CANCER CYTOPATHOLOGY

EGFR mutation detection by microfluidic technology: a validation study

(2013) Umberto Malapelle et al.   JOURNAL OF CLINICAL PATHOLOGY

Liquid biopsy: monitoring cancer-genetics in the blood

(2013) Emily Crowley et al.   Nature Reviews Clinical Oncology

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)

(2013) Dario de Biase et al.   PLoS One

Epidemiology of Lung Cancer

(2013) Carole Ridge et al.   SEMINARS IN INTERVENTIONAL RADIOLOGY

Circulating Tumor Cells: Liquid Biopsy of Cancer

(2012) C. Alix-Panabieres et al.   CLINICAL CHEMISTRY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Circulating Cancer Cells and Their Clinical Applications

(2011) E. P. Diamandis et al.   CLINICAL CHEMISTRY

Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer

(2011) Rafael Sirera et al.   Journal of Thoracic Oncology

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

(2011) Hiroyuki Yasuda et al.   LANCET ONCOLOGY

Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

(2010) Robert Pirker et al.   Journal of Thoracic Oncology

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

(2010) Carlos Camps et al.   LUNG CANCER

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

(2008) J. Bean et al.   CLINICAL CANCER RESEARCH

Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations

(2008) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY